Denmark tests unmanned robotic sailboat fleet with tensions high in the region
KOGE MARINA, Denmark — From a distance they look almost like ordinary sailboats, their sails emblazoned with the red-and-white flag of Denmark .
But these 10-meter (30-foot) -long vessels carry no crew and are designed for surveillance.
Four uncrewed robotic sailboats, known as 'Voyagers,' have been put into service by Denmark's armed forces for a three-month operational trial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
VTT has developed a degradable solar cell module to be attached to a plant leaf - agriculture needs green electronics
Globally, the digitalisation of agriculture requires the increasing use of measurement electronics in farming. However, power supply and electronic waste pose problems. VTT has now developed a biodegradable solar cell module power source in an international green electronics research project. ESPOO, Finland , June 17, 2025 /PRNewswire/ -- The solar cell module developed by VTT is so small and light that it can be attached directly to, for example, the stem of a cultivated plant or a large leaf. The cell is approximately the size of a credit card, very flexible and extremely thin. After the growing season, the cell decomposes along with the rechargeable power supply that the cell charges. "When a solar cell is used in an agricultural application, biodegradability is essential. In this case, there is no real harm caused if the cell cannot be removed from the field, even if it is in close contact with the soil. And, there are no harmful substances to leach into the environment or exacerbate the microplastics problem," says Maria Smolander, Research Team Leader at VTT. "Right now, sensors still aren't being used a great deal in agriculture, but this biodegradable solution makes it possible to more effectively implement them in agricultural applications," says Smolander. Compostable device developed in cooperation with six research institutes The aim of the three-year international research project is to create degradable cultivation sensors. In addition to VTT, Tampere University, University of Glasgow, Lukasiewicz Institute of Microelectronics and Photonics (Łukasiewicz-IMIF), Centre Suisse d'Electronique et de Microtechnique S.A. (CSEM) and McGill University contributed to the project, which was funded by the CHIST-ERA and national funding agencies (e.g. Research Council of Finland). "Although agriculture has served as a practical test platform for this green electronics project, the main idea is to explore how electronics can be made more environmentally friendly," says Liisa Hakola, Senior Scientist at VTT. In the project, VTT developed the solar cell and Tampere University developed a battery-like supercapacitor that stores energy. The project has also developed compostable sensors and modules that transmit collected data wirelessly. "The aim here is not to collect a large amount of energy - it's about low energy consumption sensors that can be used to monitor the state of the environment. The degradable solar cell is not intended to match the performance of conventional cells, and there is no need for a long service life", says Marja Välimäki, Senior Scientist at VTT. Development of a biodegradable cell set new requirements VTT has years of comprehensive experience in the manufacture of state-of-the-art solar cells. However, development of a biodegradable cell set new requirements. The structural components must not prematurely decompose or accelerate the decomposition of other components. "The biodegradable material is less resistant to environmental conditions, such as heat and moisture stress. It must also be ensured that the sensors are extremely light if they are going to be attached to a plant," says Liisa Hakola. Depending on the conditions, a biodegradable solar cell will decompose within weeks or months. Solar cell protection can be used to regulate its service life. The cell developed by VTT is made of a bio-based thin film substrate and has a partly inorganic structure. The manufactured solar cell is less than 35 micrometres thick and, even with protection added, the total thickness remains only tenths of a millimetre. Regulation requires more measurement technology for farms Measurement technologies employed on farms serve the growing needs of agricultural data collection, which is used to improve yields, combat plant diseases and reduce agricultural emissions. Regulation also requires increasingly accurate measurement data. "For example, EU regulations require that nutrient loads be studied regularly in soil samples. The new biodegradable solar cell offers a widely applicable way to collect energy, and sensoring enables more real-time data collection and environmental monitoring," explains Välimäki. VTT is also developing environmentally friendly electronics and solar cells as part of a EU funded IoT research project, whose objectives include combining sensor technology with a sustainable circular economy and clean solutions. Further information: VTT Technical Research Centre of FinlandMaria Smolander, Research Team Leader, tel. +358 (0)40 702 9933, Välimäki, Senior Scientist, tel. +358 (0)40 578 9014, Hakola, Senior Scientist, tel. +358 (0)40 841 5978, Further information on VTT:Paula Bergqvist, Communications Manager+358 20 722 5161, This information was brought to you by Cision The following files are available for download: aurinkokennomoduuli-vtt-21 View original content: SOURCE VTT Info
Yahoo
3 hours ago
- Yahoo
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers -- -- Data support planned accelerated approval BLA submission in H2 2026 -- -- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET -- SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced positive topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE™ program in Facioscapulohumeral Muscular Dystrophy (FSHD). These data as well as research supporting KHDC1L as a novel DUX4 regulated circulating biomarker will be presented in oral and poster presentations at the 32nd Annual FSHD Society International Research Congress (IRC), being held June 12-13, 2025, in Amsterdam, the Netherlands. Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD by directly targeting the disease-causing gene, double homeobox 4 (DUX4). Currently, there are no approved therapies for the treatment of FSHD, a rare, hereditary disorder marked by life-long, relentless loss of muscle strength and function, significant pain, fatigue, and progressive disability. FSHD affects approximately 45,000 to 87,000 people in the United States and Europe. "The positive topline del-brax results from FORTITUDE being presented at FSHD IRC this week are remarkable and consistent across multiple functional measures as well as biomarkers," said Sarah Boyce, president and chief executive officer at Avidity. "Based on these unprecedented data, we are rapidly advancing del-brax as we pursue accelerated approval and prepare to submit a BLA in the second half of 2026. We are incredibly grateful for the continued trust and support from study participants, their caregivers, investigators and their staff, which are paramount to the success of this program." Avidity today also announced that the accelerated approval regulatory pathway in the U.S. is open for del-brax and that the company has initiated the global, confirmatory Phase 3 FORWARD™ study in FSHD. "Del-brax data from the FORTITUDE study continue to demonstrate consistent reductions in a novel circulating biomarker across two cohorts at 12 months. I am particularly encouraged that del-brax shows favorable safety and tolerability with early and consistent trends towards benefit with del-brax compared to placebo across multiple functional and participant-reported outcome measures," said Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator. "These data indicate that by directly targeting DUX4, del-brax may be able to improve the lives of patients with FSHD and potentially meaningfully control their disease. I look forward to continued evaluation of del-brax in the FORWARD Phase 3 study and remain hopeful that it is on track to become the potentially first approved drug for FSHD." Topline Data from the Phase 1/2 FORTITUDE™ Dose Escalation Cohorts The FORTITUDE™ clinical development program includes a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate multiple doses of del-brax in participants with FSHD as well as an open-label extension study. The two dose escalation cohorts evaluated 39 participants on either 2 mg/kg or 4 mg/kg of del-brax versus placebo over a period of 12 months. In these cohorts, del-brax was given every six weeks for the first three months and then every 13 weeks thereafter. Topline data from these cohorts for del-brax treated participants, compared to placebo, demonstrated: Consistent improvement of functional mobility and muscle strength as measured by 10-Meter Walk-Run test (10MWRT), Timed Up and Go (TUG) and quantitative muscle testing (QMT) as compared to placebo; Consistent improvement in multiple measures of quality of life as measured by patient reported outcomes and compared to placebo; Rapid and significant reductions in levels of KHDC1L and creatine kinase, a biomarker of muscle damage; and Favorable long-term safety and tolerability with most adverse events (AEs) mild or moderate, with no related serious or severe adverse events and no discontinuations. Topline data from the ongoing, fully enrolled del-brax Phase 1/2 FORTITUDE biomarker cohort are anticipated in Q2 2026. The primary endpoint of the FORTITUDE biomarker cohort is reduction of KHDC1L, a novel DUX4-regulated circulating biomarker. Avidity collaborated with Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research at the Fred Hutchinson Cancer Center around the identification of the KHDC1L circulating biomarker in people living with FSHD. Video Webcast InformationThe Company is hosting an investor and analyst event today, June 9, 2025 at 8:00 a.m. ET. Avidity management will be joined by Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE™ trial investigator, to discuss these updates relating to del-brax in FSHD. The virtual event will be available via a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event. About the Phase 1/2 FORTITUDE™ and Phase 2 FORTITUDE-OLE™ trialsThe FORTITUDE™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate single and multiple doses of delpacibart braxlosiran or del-brax in 90 participants with facioscapulohumeral muscular dystrophy (FSHD). FORTITUDE is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of del-brax administered intravenously. Activity of del-brax is being assessed using key biomarkers, including DUX4-regulated muscle and circulating biomarkers and magnetic resonance imaging (MRI) measures of muscle volume and composition. Though the Phase 1/2 trial is not statistically powered to assess functional benefit, it explores the clinical activity of del-brax including measures of functional mobility and muscle strength as well as patient reported outcomes and quality of life measures. The trial has a total of three dose cohorts. The first two dose escalation cohorts evaluated 2 mg/kg or 4 mg/kg of del-brax versus placebo and were designed to assess safety as well as inform the dose and dose regimen of del-brax for additional studies. Avidity has completed enrollment in the dose escalation cohorts and identified 2 mg/kg every six weeks of del-brax as the dose for future clinical trials. The third, ongoing biomarker cohort in the FORTITUDE trial assesses the impact of del-brax 2 mg/kg every six weeks versus placebo for 12 months in people living with FSHD, ages 16-70. The primary endpoint of the biomarker cohort is reduction of KHDC1L, a novel DUX4-regulated circulating biomarker. Enrollment in the biomarker cohort is complete and blinded treatment is ongoing. Participants who complete FORTITUDE have the option to enroll in the ongoing FORTITUDE open-label extension (FORTITUDE-OLE™) study evaluating the long-term safety and tolerability of del-brax in participants living with FSHD. For more information about the FORTITUDE trial, visit the FORTITUDE study website or visit and search for NCT05747924. For more information on the FORTITUDE-OLE study click here or visit and search for NCT06547216. About Del-brax Del-brax is designed to treat the underlying cause of FSHD, which is caused by the abnormal expression of a gene called double homeobox 4 or DUX4. The abnormal expression of DUX4 protein leads to changes in gene expression in muscle cells that are associated with the life-long, progressive loss of muscle function in patients with FSHD. Del-brax aims to reduce the expression of DUX4 mRNA and DUX4 protein in muscles in people with FSHD. Del-brax consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 mRNA. Del-brax is currently in registrational-stage studies including FORTITUDE biomarker cohort and the global, confirmatory, Phase 3 FORWARD trial in individuals with FSHD. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan designation for del-brax and the FDA has granted del-brax Fast Track designation. About Facioscapulohumeral Muscular Dystrophy (FSHD)Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive, and variable hereditary muscle-weakening condition marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. It is characterized by progressive and often asymmetric skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness in muscles in the lower body. FSHD is an autosomal dominant disease caused by the aberrant expression of the DUX4 (double homeobox 4) gene in the skeletal muscle, which activates genes that are toxic to muscle cells and leads to a series of downstream events that result in skeletal muscle wasting and compromised muscle function. Skeletal muscle weakness results in physical limitations throughout the whole body, including an inability to lift arms for more than a few seconds, loss of ability to show facial expressions and serious speech impediments. These symptoms cause many people affected by FSHD to become dependent on the use of a wheelchair for mobility. Currently, there are no approved treatments for people living with FSHD. About AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking StatementsAvidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Avidity's plans to file a BLA for accelerated approval of del-brax and the timing thereof; the potential for del-brax to achieve accelerated and full approval from the FDA and the timing thereof; the status of accelerated approval as a regulatory pathway for del-brax; biomarker selection and data from the study of del-brax; topline data from the biomarker cohort of the FORTITUDE™ trial and the timing thereof; Avidity's plans to pursue full, global approval for del-brax; the potential for del-brax to improve the lives of people with FSHD; the status of the FORTITUDE trial and the cohorts therein, and the FORWARD™ trial, including without limitation progress, initiation, enrollment, design, goals and dosage levels and frequencies. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation: the data and results produced from the FORTITUDE trial as of the most recent cutoff dates may not be indicative of final results, may not support BLA submission or accelerated approval, may not be satisfactory to the FDA and other regulators, and new analyses of existing data and results may produce different conclusions than established as of the date hereof; data delivered to the FDA may not support accelerated approval pathways or BLA submissions and may not be satisfactory to the FDA, including as a result of our inability to establish that a novel biomarker may serve as a surrogate endpoint reasonably likely to predict a clinical benefit; even if approved, Avidity may not be able to execute any successful product launches; unexpected adverse side effects to, or inadequate efficacy of, del-brax that may delay or limit its development, regulatory approval and/or commercialization; later developments with the FDA and other global regulators that could be inconsistent with the feedback received to date; Avidity's approach to the discovery and development of product candidates based on its AOC™ platform is unproven and may not produce any products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of clinical trials; Avidity's dependence on third parties in connection with clinical testing and product manufacturing; legislative, judicial and regulatory developments in the United States and foreign countries; Avidity could exhaust its available capital resources sooner than it currently expects; and other risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact:Kat Lange(619) 837-5014investors@ Media Contact:Kristina Coppola(619) 837-5016media@ View original content to download multimedia: SOURCE Avidity Biosciences, Inc. Sign in to access your portfolio
Geek Girl Authority
3 hours ago
- Geek Girl Authority
THE LIBRARIANS: THE NEXT CHAPTER Recap: (S01E05) And the Memory Crystal
In The Librarians: The Next Chapter 's 'And the Memory Crystal,' the question of how much of who we are is because of who we've been is posed as a pseudo-academic, polymathic megalomaniac attempts to gain the future at the price of the past. Every team member's very existence depends on stopping the malefactor. RELATED: Catch up with our recap of the previous episode of The Librarians: The Next Chapter , 'And the Thief of Love' It's a real team-centered adventure. Like Charlie (Jessica Green) with her starry-eyed moment meeting Dame Anna (Arielle Dombasle) in The Librarians: The Next Chapter, 'And the Dance of Doom!' Lysa (Olivia Morris) goes a bit fangirl when she meets one of her heroes here. For those keeping score, so far this season, Connor (Bluey Robinson) has climbed on top of a moving ghost train and the Eiffel Tower. He gets to show off those skills again, while Charlie's in the crosshairs of the artifact's powers, and Vikram (Callum McGowan) gets to beat up a bad guy. Photograph by Aleksandar Letic The Librarians: The Next Chapter, 'And the Memory Crystal' Lysa takes Vikram to the College of Science Observatory to get him up to speed on modern science. They attend Rosalind Kirch's (Ana Sofrenović) lecture. Kirch developed a hypothesis on interstellar dust and active galactic nuclei while sitting under a tree on campus, watching the oil droplets in her tea. Dr. Stanaris (Paul Leonard Murray) introduces Dr. Kirch. RELATED: Olivia Morris Shares How The Librarians: The Next Chapter Hooked Her From Page One Dr. Kirch takes the podium and begins to speak about developing her hypothesis on X-ray emission as a predictor of an accreting black hole system. Reminiscing about the moment under the tree, she suddenly stops speaking. Her eyes flicker with a blank light. She becomes confused, and Dr. Stanaris helps her off the stage. A Sharp Mind Dulled Lysa and Vikram return to the Annex. Connor joins them. Lysa believes Dr. Kirch suffered a neuro-cognitive episode. Vikram thinks Kirch's memory loss is caused by a spell. Charlie comes in with the pendulum, having given it a tune-up. The pendulum flies out of her hand to the map table and indicates an event at the College of Science Observatory. They review Lysa's recording of Dr. Kirch speaking. Using Lysa's AI-enhanced 3D program, they're able to zoom in and freeze on the moment her eyes go blank. Lysa grudgingly admits the magical event had something to do with Kirch's memory loss. When the team finds Dr. Kirch, she is solving a hitherto unsolvable integral problem. RELATED: Read our Leverage: Redemption recaps Kirch tells them the solution came to her in a flash the night before. Lysa asks Kirch about her episode at the lecture. Kirch tells her that the famous moment under the tree has completely vanished from her memory. In its place, she now has the solution to a Millennium Prize Problem no one thought would be solved for decades. The Value of Memories After leaving Dr. Kirch, Vikram berates the younger team members, arguing that people in the modern world have stopped using their brains and hearts. As he finishes his tirade, a student walks by, describing how he couldn't remember how he got into the classroom, never mind what he needed to know to write the test. Vikram concludes the spell is spreading. After questioning the students who have lost their memories, the common thread is that they have all been to the observatory recently. Vikram vows violent vengeance on the spell-caster(s). Charlie reminds him that their mission is to contain the magic, not beat up bad guys. RELATED: TV Review: Leverage: Redemption Season 3 Vikram mistakenly addresses Lysa as Anya. He covers for the slip and quickly sends her and Connor to the Astronomy Department Office to suss out any artifacts. He and Charlie will try to figure out who is stealing the memories. Meeting the Suspects In the Astronomy Department Office, Connor and Lysa meet Dr. Stanaris's teaching assistant, Filip (Vukašin Jovanović), while Vikram introduces himself to Dr. Stanaris in the observatory. Charlie shadows Vikram and quietly examines the observatory setting and telescope. In the office, Lysa distracts Filip while Connor snoops in the back rooms. He finds an antique portfolio filled with papers and steals it. Connor finds Lysa having an unproductive conversation with a clearly uncomfortable Filip. Lysa gets Connor's hint that they should get going, and they leave quickly, to Filip's relief. RELATED: On Location: The Belgrade Fortress on The Librarians: The Next Chapter Outside, they meet up with Vikram and Charlie. Connor shows them the portfolio and explains that it contains documents kept by Nicholas Culpeper, a 17th-century artifact collector. Vikram connects Culpeper to the Crystal of Dr. John Dee. Photograph by Aleksandar Letic John Dee's Crystal John Dee, Queen Elizabeth I's court magician, used his crystal to see the future, but eventually saw something that made him lose his mind and memory. Among the Culpeper Papers, Connor finds John Dee's own papers on the crystal, an instruction manual. They're written in High Enochian, a language Dee invented, which Vikram can read. Back at the Annex, Vikram translates that the crystal is harmless when in its necklace setting. If taken out, it can grant a single, desired glimpse into the future in exchange for a memory. When the crystal is amplified to the point of clearing the past, the knowledge of the future is limitless. Some of Dee's papers are missing. RELATED: Dean Devlin Dishes on The Librarians: The Next Chapter 's Magical Homecoming Connor reports that the crystal and papers were stolen from the London Science Museum. Vikram leads the team back to the college, determined to confront Filip and Dr. Stanaris and force them to confess. Lysa and Charlie try to convince him that violence is the last resort. Suddenly, Lysa notices Filip in a very expensive car. Vikram sends Connor and Charlie to find Stanaris while he and Lysa question Filip. Suspicious Minds When Vikrim confronts Filip, the teaching assistant tries to make a getaway, but Vikrim jumps into the back of the convertible. Filip's eyes flicker blank as he's driving at top speed. He's forgotten how to drive. They swerve and careen around campus roads and plazas nonstop, somehow avoiding crashing into people, buildings, and trees. Also, not slowing down. Vikram calls Connor using his cell phone. Connor and Charlie run out of the observatory and spot Vikram and Filip on the plaza. Charlie grabs a bicycle and chases down Filip's car. Jumping into the passenger side, she pulls the emergency brake, bringing the car to a stop. She looks around, confused. When Connor and Lysa join them in the car, she doesn't know who they are. RELATED: 5 Great Books About Libraries and Librarians Vikram tries to remind Charlie of who they are and what they're doing, but she's lost the memory of Jacob Stone (Christian Kane) recalling her to be Vikram's Guardian. Elsewhere, Filip tells Lysa and Connor he bought the car with casino winnings after he had a vision of a roulette wheel. The Vault Since Charlie's memory gap is bigger than Filip's, Vikram concludes the crystal's power is growing. Connor reports that Filip told them that Stanaris traveled to England the weekend the crystal disappeared from the Science Museum. Filip believes the crystal might be in the vault in the basement. Charlie still doesn't trust the team. She suspects they are actually the Library's enemies, trying to corrupt her. Vikram sends the others on to the vault and briefs Charlie on everything she's done as part of their team in the past five weeks. In the basement, Lysa uses her AI-enhanced 3D program on her phone to enhance a still of Stanaris's face to fool the vault's retinal scan. RELATED: 10 Out-of-This-World Predictions for Resident Alien Season 4 Lysa goes outside to bring Vikram and Charlie in. As they pass through the office space, a portrait of Dr. Kirch morphs into a man. In the vault, Vikram finds the case the crystal was stored in, but it's empty. Lysa runs in with a copy of Dr. Kirch's book, only the cover image and authorship have changed to a man named Dr. Laszlo Maisch. Remembering the crystal's instructions, they realize the crystal's effect is erasing past events, not just the memories of them. Dr. Stanaris's desire for limitless knowledge of the future is costing actual historical events. Vikram deems Stanaris a 'remorseless monomaniac.' Lysa translates that as a modern-day sociopath. Magical Causality The team reasons that Stanaris must feed the crystal other people's memories to amplify its powers. Each time someone looks through the crystal, it takes more memories and grows in strength. Connor asks when Charlie would've looked through the crystal. Vikram remembers that she looked through the telescope when they visited Stanaris in the observatory. Filip and Dr. Kirch also looked through the telescope. The crystal must be in the telescope's viewer. Dr. Stanaris suddenly appears at the vault door and locks them in. Lysa tries to appeal to his conscience, but he proudly declares that he doesn't care about the effects of his plan and expresses his rage and disdain for those who have undervalued his intellect. RELATED: TV Review: Resident Alien Season 4 While they try to figure out a way to escape the vault, Lysa shares that erasing past events takes time to catch up to the present. So when Charlie's lost memory of joining the team catches up with the present, no one will save them from the drekavac (in The Librarians: The Next Chapter series premiere), and they'll be dead. Crystal Moments In the observatory, a magical bubble forms around the telescope's viewer. In the vault, Connor recalls that museum security systems like the vault's have a fire override failsafe. Lysa finds the sensor in the ceiling. Connor hands her a lighter to trigger it, opening the vault door. The magical bubble in the observatory grows to fill the room. Stanaris holds the necklace setting in his hand and steps inside. Connor and Lysa run into the bubble and immediately become confused. Charlie and Vikram reach through, pull them out, and drag them into a corridor. To get the crystal away from Stanaris, Vikram intends to enter the bubble himself, arguing that his mental discipline will protect him from the effects of the crystal. RELATED: Revival : The Dead Have Rejoined the Living in Official Trailer Vikram enters the bubble. Stanaris wonders how he can resist the crystal's effects. Vikram claims to be able to partition his memories from his active brain. He holds onto what he needs and gives away meaningless memories to the crystal's appetite for energy. It's still a struggle, though. He stumbles closer to Stanaris and the telescope's viewer. Stanaris suddenly asks what Vikram values most in the world. Involuntarily, Vikram thinks of Anya, and the crystal consumes his memory of her. An Upper Hand Losing Anya breaks Vikram mentally, and he falls to the ground. Stanaris smiles in victory, asking Vikram innocently if he forgot something. Downstairs, in the mechanical room, Charlie shows Connor and Lysa that her hand is phasing out of existence. Connor runs outside and climbs to the top of the observatory. In the bubble, Stanaris pulls out the John Dee papers he kept, which explain that wearing the crystal's necklace protects the wearer from the crystal's effects. Down in the mechanical room, Lysa holds Charlie as other parts of the Guardian's body begin to fade. She begs Charlie to fight the effects. RELATED: Revival : Check Out 9 First-Look Photos From Melanie Scrofano-Led Series Connor reaches the opening in the observatory's roof just as the crystal's bubble grows bigger than the observatory. Once engulfed, he forgets why he's up there and falls through, barely holding onto the ledge. Vikram looks up and sees Connor. This jolts his memory for a moment, and when Stanaris also sees Connor hanging from the observatory's opening, Vikram sneaks up and rips the necklace off him. Vikram throws the necklace to Connor. When Connor catches it, he remembers why he's there. He leaps onto the telescope and slides down it, breaking the viewer off and knocking the crystal loose. Photograph by Aleksandar Letic Magic Managed Stanaris picks up the crystal with no idea what it is. Vikram knocks it out of his hand with his cane at Connor. On the backswing, he knocks Stanaris to the ground. Connor pops the crystal back into the necklace, and the bubble disappears. Running down to the mechanical room, Vikram and Connor are relieved to see Charlie whole and happy. The next day, Lysa sits down with Dr. Kirch, who describes the sensation of disappearing, then remembering the moment when she developed her hypothesis. Lysa notes that Kirch has erased the solution to the Millennium Prize Puzzle equation. Kirch tells her she didn't trust the equation, not knowing how it popped into her head. 'Scientific advancement,' she tells Lysa, 'should come through replication of scientific method.' RELATED: Read our recaps of The Librarians: The Next Chapter Back at the Annex, the team debriefs on everyone affected by the crystal as Vikram packs it and John Dee's papers into a lockbox. Charlie reports she's feeling better. Vikram asks her what vision of the future she saw. She unconvincingly claims it disappeared once the crystal was contained. Connor wonders where Stanaris ended up. In a white room, Stanaris lectures on the reverse amplified view of the universe, claiming it proves that the great minds of science added nothing to the world compared to him and his glimpse into the future. He rants that he'd still be viewing the future if it wasn't for those meddling Librarians. New episodes of The Librarians: The Next Chapter air on TNT on Mondays at 9 pm ET. REVIVAL: Co-Creators Aaron B. Koontz and Luke Boyce on Crafting 'Weird' New Series Diana lives in Vancouver, BC, Canada, where she invests her time and energy in teaching, writing, parenting, and indulging her love of all Trek and a myriad of other fandoms. She is a lifelong fan of smart sci-fi and fantasy media, an upstanding citizen of the United Federation of Planets, and a supporter of AFC Richmond 'til she dies. Her guilty pleasures include female-led procedurals, old-school sitcoms, and Bluey. She teaches, knits, and dreams big. You can also find her writing at The Televixen, Women at Warp, TV Fanatic, and TV Goodness.
